Summary by Moomoo AI
On May 9, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the first quarter ended March 31, 2024. The company, which is based in South San Francisco, California, and incorporated in Delaware, is listed on the Nasdaq Capital Market under the trading symbol SNTI. Senti Biosciences reported cash and cash equivalents of $23.7 million and an additional $18.9 million in receivables from the GeneFab transaction. Research and development expenses increased to $8.8 million, up from $7.1 million in the same period the previous year, primarily due to manufacturing costs for the company's programs. General and administrative expenses decreased to $7.5 million from $9.2 million, attributed to a reduction in workforce earlier in the year. The net loss for the...Show More